Date: 2012-10-30
Type of information: Production agreement
Compound: PASylated therapeutic proteins
Company: Wacker Biotech (Germany) XL-protein (Germany)
Therapeutic area:
Type agreement: collaboration
production
manufacturing
Action mechanism:
Disease:
Details: Wacker Biotech and XL-protein have announced the signature of an agreement to collaborate more intensely on the production of PASylated therapeutic proteins. Through this collaboration, Wacker and its customers will gain access to XL-protein’s PASylation® platform. The PASylation® technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. In a recent feasibility study, PASylated human growth hormone was successfully produced in high yields using Wacker’s E. coli-based ESETEC® technology. The study showed that ESETEC® produced a PASylated human growth hormone – correctly folded and fully functional – in high yields (3 to 4 g/l). Moreover, Wacker successfully used its secretion technology to develop an E. coli cell line for manufacturing the PASylated hormone.
Financial terms:
Latest news:
